sever
combin
immunodefici
scid
rare
disord
defin
profound
development
function
defect
lymphocyt
unrecogn
caus
death
first
year
life
due
lifethreaten
increas
suscept
infect
therefor
earli
detect
treatment
scid
infect
becom
overwhelm
optim
surviv
today
form
scid
treat
hematopoiet
stem
cell
transplant
hsct
hsct
success
genet
treatment
option
altern
patient
lack
human
leukocyt
antigen
hla
match
sibl
unrel
stem
cell
donor
urgent
need
hsct
hlahaploident
parent
donor
often
readili
avail
given
major
hla
donorrecipi
dispar
haploident
set
measur
requir
prevent
occurr
alloreact
respons
ie
graft
reject
sever
graftversu
hostdiseas
gvhd
extens
exvivo
deplet
donor
tcell
clinimac
system
proven
effici
prevent
gvhd
inevit
coupl
delay
earli
tcell
recoveri
thu
increas
risk
viral
infect
recent
effort
balanc
risk
gvhd
delay
immun
reconstitut
includ
select
deplet
gvhdinduc
alphabeta
tcell
retain
potenti
benefici
gammadelta
tcell
haploident
graft
unselect
donor
lymphocyt
infus
dli
frequent
use
tool
boost
antivir
immun
posttranspl
harbor
signific
risk
induc
sever
gvhd
haploident
set
gvhdinduc
cell
resid
mainli
tcell
popul
wherea
viralspecif
memori
tcell
predominantli
thu
deplet
cell
dli
may
provid
potenti
broad
repertoir
donorderiv
viralimmun
limit
risk
gvhd
herein
report
success
treatment
scid
combin
cell
receptor
tcr
deplet
haploident
hsct
deplet
dli
antivir
boost
male
patient
born
full
term
normal
pregnanc
third
child
afghanistani
relat
parent
parent
sibl
healthi
first
upper
respiratori
tract
infect
urti
age
week
age
month
admit
first
time
pediatr
ward
week
cough
low
grade
fever
hoars
follow
month
follow
regularli
due
cough
hoars
failur
thrive
age
month
infect
chickenpox
three
week
onset
infect
new
blister
still
form
varicella
kerat
develop
unusu
sever
cours
infect
failur
thrive
warrant
investig
primari
immunodefici
disord
pid
conform
protocol
routin
blood
investig
first
month
life
show
normal
leukocyt
neutrophil
count
sever
occas
total
lymphocyt
measur
first
admiss
month
age
low
valu
ref
attribut
upper
respiratori
tract
infect
urti
follow
begin
chickenpox
infect
level
laboratori
test
includ
electrolyt
alt
ast
gt
pancreat
amylas
bilirubin
organ
acid
amino
acid
thyroid
hormon
statu
normal
time
point
pid
investig
anem
hemoglobin
gl
normal
platelet
total
lymphocyt
count
immunolog
investig
reveal
low
tcell
count
confirm
tb
nk
scid
phenotyp
cultur
taken
point
show
multipl
infect
posit
staphylococcu
aureu
blood
cultur
cytomegaloviru
cmv
varicella
viru
dna
posit
blood
varicella
dna
cerebrospin
fluid
pneumocysti
jiroveci
coronaviru
throat
swab
rotaviru
fece
high
serum
betadglucan
genom
dna
prepar
blood
collect
edta
fragment
averag
length
bp
exom
enrich
use
sureselect
xt
human
exon
technolog
agil
sequenc
carri
averag
coverag
use
pe
bp
sequenc
illumina
hiseq
bioinformat
analysi
carri
use
mutat
identif
pipelin
mip
result
present
interact
browserbas
visual
tool
scout
develop
inhous
scienc
life
laboratori
solna
sweden
clinic
interpret
result
restrict
predefin
set
gene
known
involv
primari
immunodefici
sequenc
chang
exon
exonintron
boundari
analyz
rare
variant
allel
frequenc
consid
recess
diseas
gene
least
two
variant
requir
analysi
design
detect
structur
rearrang
copi
number
alter
exon
sequenc
restrict
predefin
set
immunodefici
gene
identifi
lowfrequ
variant
could
account
patient
clinic
present
homozyg
missens
variant
gene
identifi
receiv
low
rank
score
due
report
high
frequenc
genom
databas
therefor
consid
natur
variant
thu
known
genet
defect
identifi
consid
low
number
lymphocyt
lifethreaten
infect
decis
made
perform
hsct
parent
provid
written
inform
consent
procedur
hla
match
sibl
avail
probabl
find
match
unrel
donor
consid
low
given
ethnic
origin
consequ
choic
made
select
hlahaploident
parent
donor
patient
parent
investig
accord
institut
protocol
haploident
hsct
includ
high
resolut
allel
type
hla
b
c
pcrsequenc
specif
primer
ssp
olerup
ssp
ab
hladonor
specif
antibodi
dsa
labscreen
singel
antigen
luminex
platform
one
lambda
thermo
fisher
aboblood
group
cmvserolog
mother
select
donor
base
outcom
pretranspl
investig
select
support
report
higher
surviv
rate
haploident
hsct
patient
graft
mother
compar
recipi
patern
graft
hlatyp
confirm
patient
donor
haploident
allel
match
hostversusgraft
direct
dsa
detect
serum
patient
donor
match
aboblood
group
cmv
posit
patient
condit
myeloabl
regimen
accord
guidelin
regard
hsct
primari
immunodefici
haploident
famili
donor
patient
older
month
howev
due
poor
health
statu
decid
use
reduc
intens
regimen
condit
consist
iv
antithymoglobulin
atg
freseniu
given
day
first
day
mgkg
bodyweight
mgkg
bodyweight
fludarabin
day
thiotepa
mgkg
twice
day
day
melfalan
day
sole
form
gvhd
prevent
immunomagnet
deplet
cell
graft
prophylaxi
posttranspl
virusassoci
lymphoprolif
diseas
ebvptld
consist
one
dose
rituximab
given
day
posttransplant
pharmacolog
immunosuppress
use
peripher
blood
progenitor
cell
pbpc
haploident
matern
donor
mobil
granulocytecolonystimul
factor
gcsf
collect
leukapheresi
cobe
spectra
terumo
bct
day
gcsf
administr
collect
pbpc
process
clean
room
condit
clinimac
system
miltenyi
biotech
accord
protocol
cell
sequenti
label
reagent
clinimac
antibiotin
reagent
process
clinimac
devic
use
program
deplet
tube
set
dt
graft
cell
content
determin
flow
cytometr
analysi
fac
canto
ii
becton
dickinson
bd
use
antibodi
viabil
marker
bd
accord
institut
protocol
haploident
hsct
target
cell
dose
deplet
graft
set
cellskg
minimum
cellskg
maximum
tcr
kg
bag
unmobil
whole
blood
drawn
donor
util
close
blood
bag
system
whole
blood
separ
densiti
centrifug
obtain
leukocyt
enrich
cell
fraction
process
clinimac
system
accord
protocol
cell
label
reagent
process
clean
room
condit
clinimac
devic
use
program
dt
cell
content
target
fraction
assess
fac
canto
ii
bd
use
antibodi
viabil
marker
bd
engraft
follow
hsct
monitor
daili
count
leukocyt
neutrophil
platelet
immun
recoveri
assess
post
hsct
dli
fac
canto
ii
bd
peripher
blood
lymphocyt
use
antibodi
bd
donor
myeloid
tcell
chimer
monitor
dna
genotyp
short
tandem
repeat
polymorph
pcrstr
dx
genet
analyz
appli
biosystem
patient
evalu
sign
acut
chronic
gvhd
procedur
follow
accord
ethic
standard
helsinki
declar
revis
region
ethic
review
board
lund
sweden
advis
us
sign
consent
patient
parent
suffici
public
case
consent
obtain
singl
leukapheresi
procedur
provid
cellskg
recipi
weight
subsequ
deplet
clinimac
system
deplet
rate
correspond
cell
target
fraction
recoveri
cell
cell
cell
viabil
postsort
graft
contain
per
kg
recipi
weight
cell
cell
cell
bcell
nkcell
transplant
total
patient
donor
antibodi
cmv
vzv
ebv
herp
simplex
hematolog
recoveri
post
hsct
prompt
white
blood
cell
count
day
neutrophil
day
thrombocyt
day
complet
myeloid
tcell
donor
chimer
reach
day
expect
nkcell
coinfus
graft
expand
rapidli
normal
peripher
count
day
ref
howev
despit
prompt
threelinear
hematolog
recoveri
patient
remain
profoundli
tcell
lymphopen
fig
atg
clearanc
vari
individu
efficaci
atg
vari
batch
therefor
explan
lymphopenia
could
sinc
use
atg
rel
high
dose
given
timewis
quit
close
graft
affect
graft
henc
could
consid
addit
vivo
tcell
deplet
due
persist
effect
rituximab
bcell
recoveri
also
markedli
delay
singl
unit
donor
whole
blood
provid
surplu
cell
recipi
weight
subsequ
deplet
use
clinimac
system
cell
deplet
rate
correspond
residu
cell
target
fraction
recoveri
cell
cell
viabil
postsort
target
fraction
contain
cell
cell
per
kg
recipi
weight
increas
ratio
compar
start
product
versu
aliquot
deplet
product
contain
cellskg
recipi
weight
prepar
fresh
dli
cryopreserv
patient
receiv
fresh
deplet
dli
cellskg
origin
hsct
donor
day
post
hsct
time
dli
day
post
hsct
peripher
blood
level
l
reach
l
respect
day
follow
dli
day
dli
tlymphocyt
subset
count
normal
fig
correspond
continu
complet
donor
tcell
chimer
circul
tcell
predominantli
l
l
patient
experi
acut
gvhd
hsct
dli
earli
posttranspl
period
complic
day
acut
mechan
ileu
unknown
etiolog
resolv
mechan
manipul
exploratori
laparotomi
blood
test
show
continu
vzv
posit
number
cmv
copi
increas
condit
deterior
suffer
enterococcu
faecium
septicemia
day
follow
sever
diarrhea
gastrointestin
tract
bleed
sign
probabl
coliti
stool
analysi
reveal
cmv
addit
rotaviru
two
week
dli
test
result
show
cmv
resist
ganciclovir
therefor
antivir
treatment
chang
foscarnet
follow
dli
time
clearanc
vzv
rotaviru
day
cmv
level
decreas
rapidli
fig
patient
condit
improv
consider
stool
analysi
cmv
neg
day
follow
dli
clear
peripher
blood
day
supplement
immunoglobulin
discontinu
day
post
hsct
discharg
approxim
month
post
hsct
chronic
gvhd
observ
hsct
dli
develop
blind
onesid
microphthalmia
due
varicella
kerat
month
hsct
patient
normal
lymphocyt
count
normal
lymphocyt
subset
neither
new
exacerb
preexist
infect
observ
allogen
hsct
cur
treatment
avail
scid
although
associ
high
incid
sever
infect
increas
risk
gvhd
earli
intervent
crucial
prognost
factor
prompt
avail
parent
donor
may
favor
hlahaploident
donor
altern
haploident
hsct
protocol
util
extens
ex
vivo
tcell
deplet
graft
proven
effici
prevent
gvhd
remain
challeng
enhanc
posttranspl
immunereconstitut
address
sever
investig
util
partial
tcell
deplet
graft
adopt
transfer
donor
immun
cell
present
novel
approach
treat
scid
combin
deplet
haploident
hsct
deplet
dli
therapeut
antivir
boost
patient
receiv
deplet
graft
haploident
mother
follow
reduc
intens
condit
regimen
short
cours
atg
singl
dose
rituximab
prevent
ebvptld
addit
gvhd
prophylaxi
engraft
rapid
complet
donor
chimer
sign
gvhd
howev
week
post
hsct
patient
still
tcell
lymphopen
clinic
symptom
multipl
sever
viral
infect
consequ
decis
made
initi
therapeut
dli
enhanc
antivir
immun
haploident
set
unselect
dli
tcell
addback
cellskg
may
caus
sever
gvhd
contrast
enrich
memori
tcell
may
provid
viral
immun
markedli
reduc
alloreact
notwithstand
crossreact
memori
viralspecif
tcell
mismatch
hla
describ
thu
potenti
sourc
gvhd
haploident
hsct
base
observ
patient
treat
deplet
haploident
donor
lymphocyt
transfer
total
tcell
dose
cellskg
puriti
memori
tcell
follow
dli
prompt
increas
count
observ
concomit
reduct
viral
load
subsequ
clearanc
viral
infect
acut
chronic
gvhd
observ
previous
demonstr
cell
could
effici
deplet
log
clinimac
instrument
preserv
high
number
cell
potenti
benefici
tcrgd
cell
nkcell
graft
current
approach
transfer
low
dose
deplet
donor
tcell
cell
sampl
donor
peripher
blood
provid
suffici
number
lymphocyt
ensur
manufactur
dli
complianc
good
manufactur
process
gmp
condit
close
blood
bag
system
use
collect
leukocyt
enrich
donor
whole
blood
clinimac
instrument
use
subsequ
deplet
tcell
effici
deplet
log
provid
suffici
number
cell
fresh
dli
cryopreserv
benefit
current
protocol
time
cost
effect
use
whole
blood
donat
rather
leukapheresi
product
start
materi
moreov
approach
also
less
strenuou
donor
longstand
approach
control
refractori
viral
infect
follow
hsct
gener
antigenspecif
tcell
singl
pathogen
cmv
adenoviru
ebv
new
strategi
develop
ex
vivo
select
pathogenspecif
donor
tcell
use
antigen
induc
stimul
isol
cytokin
secret
assay
hlapeptid
streptam
howev
approach
time
consum
technic
much
demand
simpl
method
cell
deplet
base
surfac
antigen
express
also
gener
antigen
stimul
tcell
clinic
applic
subject
complex
regulatori
framework
deplet
unmanipul
lymphocyt
recent
often
limit
therapeut
effect
use
antigenspecif
tcell
attribut
limit
vivo
persist
transfer
donor
tcell
suggest
adopt
transfer
includ
varieti
donor
tcell
popul
favor
longlast
clinic
respons
recent
three
differ
group
investig
use
deplet
part
haploident
hlamismatch
donor
graft
process
use
differ
condit
regimen
differ
stem
cell
sourc
graft
composit
without
serotherapi
two
group
report
limit
gvhd
despit
high
number
transfer
tcell
x
third
group
report
incid
grade
iiiiv
acut
gvhd
studi
requir
determin
optim
time
tcell
dose
sourc
deplet
donor
lymphocyt
part
graft
prophylact
preemptiv
therapeut
dli
autom
deplet
tcell
unmobil
whole
blood
donat
simpl
rapid
strategi
provid
unmanipul
dli
potenti
broad
repertoir
pathogen
specif
memori
tcell
haploident
set
therapeut
deplet
dli
safe
administ
low
tcell
dose
effici
enhanc
viral
immun
limit
risk
gvhd
demonstr
success
approach
follow
deplet
hsct
treatment
scid
